Microbot Med Inc Stock Price, News & Analysis

Microbot Medical Inc. (Nasdaq: MBOT) announced the issuance of a Notice of Allowance for its LIBERTY® Robotic System by the USPTO, marking a significant milestone in its intellectual property portfolio, which now consists of 45 patents issued/allowed and 24 pending applications. CEO Harel Gadot emphasized this achievement as crucial for securing a competitive edge and advancing commercialization of their technology aimed at enhancing catheter-based procedures while minimizing risks for physicians. The patent covers a device designed to automate the manipulation of surgical tools within bodily lumens.

Microbot Medical (Nasdaq: MBOT) announced a Notice of Allowance (NOA) for its 'One & Done' guidewire technology in China, adding to previous approvals in the European Union, Japan, and Israel. With a total of 44 patents allowed or issued and 24 pending globally, the company aims to enhance patient outcomes and strengthen its competitive position. The double guidewire technology includes features for adjusting curvature and stiffness, indicating advancements in micro-robotic applications for healthcare.

Microbot Medical (NASDAQ: MBOT) has strengthened its Scientific Advisory Board with the addition of Dr. Giora Weisz, a renowned interventional cardiologist. Dr. Weisz's extensive experience in robotic-enhanced coronary interventions, particularly his role in the FDA-approved CorePath system, is expected to aid Microbot in advancing its LIBERTY Robotic System. CEO Harel Gadot emphasized the significance of Dr. Weisz's involvement in enhancing the system to address the growing cardiac market. Microbot specializes in micro-robotic technologies aimed at improving patient outcomes.

Microbot Medical Inc. (Nasdaq: MBOT) has received a Notice of Allowance from the Israel Intellectual Property Office for its innovative 'One & Done' guidewire technology. This patent joins previously granted approvals in Europe and Japan, enhancing Microbot's global patent portfolio to 42 issued/allowed patents and 23 pending applications. CEO Harel Gadot emphasized the importance of this technology for the company's future development and competitive edge in the micro-robotic medical field.

Microbot Medical Inc. (Nasdaq: MBOT) has been notified by the Japan Patent Office (JPO) that it intends to grant a patent for its innovative ‘One & Done’ guidewire technology aimed at endoluminal interventions. This marks Japan as the second jurisdiction to recognize this patent, enhancing the company’s intellectual property protection. CEO Harel Gadot highlighted the positive feedback from the medical community regarding their LIBERTY™ Robotic system and noted that the allowed claims cover a dual guidewire structure with adjustable states. Currently, Microbot holds 41 issued patents and has 22 pending applications.

Microbot Medical Inc. (Nasdaq: MBOT) announced successful discussions with the FDA regarding its Self-Cleaning Shunt (SCS). The FDA's feedback allows the company to apply for an Early Feasibility Study (EFS), paving the way for a First-in-Human (FIH) clinical trial projected for Q3 2022. CEO Harel Gadot highlighted this as a significant milestone, noting confidence in the strength of their pre-clinical data. This innovative device aims to prevent obstruction in cerebrospinal fluid catheters for patients with hydrocephalus.

Microbot Medical (Nasdaq: MBOT) has expanded its Scientific Advisory Board (SAB) with five renowned medical experts to enhance its leadership in micro-robotic technologies. The newly appointed members include specialists in interventional radiology and stroke therapy, such as Stephen B. Solomon, MD, and Ajay K. Wakhloo, MD PhD FAHA. CEO Harel Gadot emphasized the importance of attracting top talent to achieve significant clinical and regulatory milestones. Microbot Medical focuses on developing transformative technologies for minimally invasive procedures, contributing to advancements in the healthcare sector.

Microbot Medical (Nasdaq: MBOT) successfully completed an additional feasibility animal study of its LIBERTY™ Robotic System, achieving key study endpoints without any intraoperative adverse events. This study confirms LIBERTY's potential to enhance the safety and ease of conducting catheter-based neurovascular procedures remotely, minimizing risks associated with radiation exposure and contamination. CEO Harel Gadot expressed confidence in the system's performance and usability in clinical settings, with plans for further studies in the upcoming year to meet regulatory objectives.

Microbot Medical (Nasdaq: MBOT) has reported significant achievements for 2020, including the launch of the LIBERTY™ Robotic System, the first fully disposable surgical robotic system. Animal feasibility studies showed no adverse events, supporting remote catheter procedures to minimize physician risk. The company expanded its intellectual property with 40 patents granted. Leadership strengthened with new CMO and Board members, enhancing strategic capability. Looking ahead, Microbot aims to finalize FDA submissions for its technologies and continue exploring M&A opportunities in 2021.